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ABSTRACT
Background: The incidence of postoperative nausea and vomiting (PONV) following general
anesthesia remains high despite the increasing number of healthcare advances. Aprepitant has
demonstrated promising effectiveness in the prevention of PONV and can add value to current
healthcare practices. Further investigation is needed to determine aprepitant’s effectiveness and
best use to create practice recommendations.
Objectives: (1) To evaluate the effectiveness of aprepitant versus ondansetron in the prevention
of PONV utilizing three databases: PubMed, CINAHL, and EMBASE. This systematic review
will serve as the basis for objective two. (2) To demonstrate an increase in knowledge of
anesthesia providers pertaining to the use of aprepitant in the prevention of PONV.
Methodology: Ten articles, including eight randomized controlled trials (RCTs) and two
systematic reviews, were deemed eligible for use in this systematic review. Based on the evidence
from these ten articles, aprepitant was found to have superior protection against PONV in
comparison to ondansetron; aprepitant in combination with ondansetron was shown to have more
effectiveness than ondansetron alone against PONV; and aprepitant demonstrated improved
effectiveness in the prevention of postoperative vomiting and time to first vomiting episode. With
this information, a pre-test, educational module, and post-test were created for anesthesia
providers to evaluate baseline knowledge and knowledge growth.
Results: The statistical analysis between the pre-test and post-test demonstrated an increase in
provider knowledge on PONV and use of aprepitant.
Conclusions: Aprepitant administered alone along with aprepitant administered with ondansetron
is more effective than ondansetron alone in reducing PONV rates. Implementation of an
educational based intervention increased providers knowledge on information pertaining to
aprepitant and its use in the prevention of PONV. Continual implementation of this quality
improvement project has the potential to lead to decreased PONV rates, improved patient
outcomes, and increased patient satisfaction.
Keywords: Aprepitant, Antiemetic, Ondansetron, Nausea, Vomiting, Postoperative nausea and
vomiting (PONV)
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INTRODUCTION
Description of the Problem
The National Library of Medicine defines postoperative nausea and vomiting (PONV) as
nausea and/or vomiting that occurs immediately in the first 24 hours after surgery.1 PONV, along
with pain, is one of two of the most common patient complaints reported after surgery and is the
leading cause of unplanned inpatient admissions.1 There have been various guidelines published
from different societies regarding pharmacological and nonpharmacological treatments to prevent
PONV, yet PONV rates remain high.1 PONV rates remain high despite improvements in
healthcare, including the availability of multiple prophylactic antiemetic agents, the use of
minimally invasive surgical techniques, and the availability of short-acting anesthetics.2 The
incidence rates for inpatient surgeries range between 30% to 50%, with rates as high as 70% to
80% for patients with multiple risk factors.3 It has been argued that the continued high incidence
is related to the increasing number of ambulatory surgeries and the increased emphasis on earlier
mobilization and discharge.2
In the United States, more than 40 million people each year will undergo surgery.4 At
least 30% of those people will experience PONV if no intervention is instituted.4 Even patients
with no known risk factors still have a 10% chance of developing PONV after surgery.4 Effects of
PONV can range anywhere from postoperative patient dissatisfaction or distress to postoperative
morbidity.4 Patient dissatisfaction with anesthesia seems to be a glaring negative consequence of
PONV. In one study of surgical patients, patients reported nausea and vomiting as 2 of the top 3
most concerning possible anesthesia outcomes, along with pain.1 Vomiting was rated as number
1, followed by pain at number 2, and nausea at number 3.1 Patients have also reported that they
were willing to pay up to $100 out of pocket for medications that would prevent PONV.3
Unfortunately, patient dissatisfaction is not the only consequence of ignoring this problem.
PONV has been implicated as the cause of delayed PACU discharge, resulting in up to twice the
time in PACU than patients who did not experience symptoms.3 Not only is this a problem for
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patients but for the efficiency of patient flow from the operating room to PACU.3 Disruption of
patient flow can result in increased healthcare spending.3 Additionally, PONV can produce
patient complications, including pulmonary aspiration, wound dehiscence, esophageal rupture,
subcutaneous emphysema, pneumothorax, and more.3
It is evident that PONV remains a current problem in anesthesia. Extensive research has
contributed to improvements in PONV, yet there is still no established antiemetic regimen.2 More
comprehensive research needs to be completed regarding the most effective prophylactic
regimen. Failure to address this problem will result in continued patient dissatisfaction with
anesthesia, lengthened post-anesthesia recovery unit (PACU) stays, and increased healthcare
costs, among other things.3
Background and significance
The pathogenesis of nausea and vomiting is extremely complex, making treatment and
prevention much more challenging despite the abundance of published studies.5 The mechanism
of vomiting can result from stimulation of five different afferent pathways: the chemoreceptor
trigger zone, vagal stimulation via the gastrointestinal system, neuronal activation of the
vestibular system, reflex afferent pathways from the cerebral cortex, and afferent pathways from
the midbrain.5 Input from any one of these pathways to the vomiting center, located in the
medulla oblongata, will result in the vomiting reflex via agonism or antagonism of a variety of
different receptors.1 Therefore, many drugs can be used as a multimodal treatment for nausea and
vomiting. However, PONV has been proven to be much more challenging to treat once it ensues.1
Prevention has been recognized as the best method for decreasing PONV’s incidence.1
Therefore, identification of high-risk patients and knowledge of associated risk factors are pivotal
to reducing rates. A preoperative risk assessment tool used to identify high-risk patients is the
Apfel scoring system, which is based on four independent risk factors.5 These include female
gender, non-smoking status, history of PONV and/or motion sickness, and use of postoperative
opioids.6 Of these four risk factors, female gender has the most significant influence on the
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incidence of PONV, with females being three times more likely than males to develop PONV.6
For this reason, the female population, requires a more calculated and comprehensive approach to
PONV prophylaxis. According to the Apfel scoring system, female gender alone places patients
at a 20% risk for developing PONV.6 Each additional risk factor on the scoring system increases
patients’ risk by 20%.6 For example, patients with an Apfel score of 4 have an 80% chance of
developing PONV without any intervention.6
Other risk factors for PONV include surgical procedure, anesthetic drug of choice, and
duration of surgery.1,5 For example, laparoscopic and gynecological surgeries tend to have a
higher incidence of PONV.5 Surgeries lasting longer than 30 minutes may increase the risk of
PONV by up to 60%.5 Additionally, specific anesthetic agents such as nitrous oxide and volatile
anesthetics increase PONV risk.5 Some modifiable risk factors that can be adjusted to decrease
the risk of PONV for a selected patient could include the anesthetic of choice or the use of
antiemetic agents.3 However, many risk factors are nonmodifiable, such as female gender and
surgical procedure.3 For example, the anesthesia provider may choose a total intravenous
approach (TIVA) over inhaled anesthetics. However, the patient may still be a young female with
a history of PONV presenting for a gynecological surgery. All of these circumstances place the
patient at high risk for PONV.3 Therefore, an effective prophylactic regimen must be established.
Anesthesia providers must be able to identify patients with nonmodifiable risk factors and treat
them appropriately. It is important to note that the American Society of Anesthesiologists
recommends PONV prophylaxis only when risk factors exist.1 Many of the antiemetics in
practice accompany undesirable side effects where risks for PONV prevention outweigh the
benefits.1
There are a large number of antiemetic drugs approved for treatment and prevention of
PONV, which include 5-hydroxytryptamine (5-HT3) receptor antagonists, corticosteroids,
butyrophenones, neurokinin-1 (NK-1) receptor antagonists, etc.2 Nonetheless, patients given
antiemetics such as the commonly used 5-HT3 antagonist, ondansetron, still experience PONV
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30% to 40% of the time.7 Multiple studies have shown that combination therapy with antiemetic
agents from different drug classes is more effective than single-agent antiemetic treatment.8
Consensus guidelines published by the American Society of Anesthesiologists (ASA) in
January of 2014 set forth eight different recommendations for the management of postoperative
nausea and vomiting.9 The ASA recommends (1) identification of patients’ at risk for PONV (2)
reduction of baseline patient risk factors for PONV (3) administration of PONV prophylaxis with
1 to 2 interventions for adults at moderate risk (4) administration of 2 or greater interventions for
patients at high risk for PONV (5) administration of prophylactic therapy to children at increased
risk for postoperative vomiting (6) administration of antiemetic agents to patients with PONV
who did not receive prophylaxis or in with whom prophylaxis failed (7) institution of PONV
prevention treatment in the clinical setting and (8) use of general multimodal prevention to
streamline implementation of PONV policies.9 While these guidelines may help guide anesthesia
providers in preventing PONV, they do not provide specific instructions on which antiemetic
agent is most efficacious for a given patient population.
Systematic Review Rationale
There has been minimal use of the class of antiemetics drugs known as neurokinin-1
(NK-1) antagonists despite their promising effectiveness.7 NK-1 antagonists are a relatively new
class of antiemetics used to prevent nausea and vomiting.7 One drug in this class, aprepitant, has
been approved and shown to be effective for the treatment of chemotherapy-induced nausea and
vomiting when used in combination with other antiemetics.7 Recently, more studies have been
conducted regarding its effectiveness in the treatment and prevention of postoperative nausea and
vomiting.
Aprepitant works primarily in the nucleus tractus solitarius as well as in areas of the
reticular formation by antagonizing NK-1 receptors to exert its antiemetic effects.5 One particular
point of interest in antagonism of the NK-1 receptor is its ability to block the effects of the
substrate substance P.8 Substance P is the most abundant neurokinin found in the central and
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peripheral nervous system.8 It is released in response to input from the gut and the brain, leading
to activation of NK-1 receptors, resulting in the vomiting reflex.8 Activation of NK-1 receptors in
response to up-regulation of receptors in cortical neurons is also thought to be the cause of
opioid-induced nausea and vomiting.10 Therefore, it is reasonable to consider that aprepitant may
effectively prevent nausea and vomiting associated with opioid administration.10
Aprepitant is recommended for administration 3 hours or less before induction of
anesthesia at a dose of 40 mg PO for PONV prophylaxis.4 A unique characteristic of aprepitant is
its particularly long half-life of 40 hours, unlike most antiemetics.9 In two large randomized
controlled trials, aprepitant has displayed similar effectiveness to the commonly administered
5HT-3 antagonist, ondansetron, in the prevention of vomiting and use of rescue antiemetics
within the first 24 hours after surgery.9 However, aprepitant was shown to be noticeably more
effective in reduction of nausea and vomiting at 24 and 48 hours post-surgery.9 Aprepitant has
also displayed greater antiemetic efficacy in comparison to ondansetron.9
While some studies have proven the promising nature of aprepitant’s antiemetic effects
and use in the prevention of PONV, more studies need to be conducted to fully establish its
effectiveness and best use.9 Further information is needed regarding the most effective use for
routine prophylaxis, the patient population that would benefit most from aprepitant’s
administration, and for which medications that it may show an additive or synergistic
relationship.9 It has been argued that aprepitant should be administered for PONV prophylaxis
specifically in patients at risk for PONV with whom vomiting could result in serious
complications, and in patients in which concerns for adverse side effects exist regarding
administration of less costly antiemetics, such as ondansetron.2
Objectives of the Systematic Review
The purpose of this systematic review is to locate all current evidence on the efficacy of
aprepitant in comparison to ondansetron for postoperative nausea and vomiting. Each chosen
study will be analyzed for significant findings related to aprepitant’s effectiveness compared to
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the antiemetic ondansetron in the prevention of PONV, specifically in patients 18 years or older.
This systematic review answered the PICO question: “(P) In patients 18 years or older
undergoing general anesthesia, (I) does the administration of aprepitant, including the
combination of aprepitant with ondansetron, (C) compared to ondansetron alone (O) reduce
incidence rates of PONV?”
METHODOLOGY
Databases and Search Strategy
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist
was used to conduct the search for this review.11 The formatting of this paper was also
accomplished in accordance with PRISMA guidelines.11 The three databases used to complete the
search for this review were PUBMED, Excerpta Medica Database (EMBASE), and Cumulated
Index to Nursing and Allied Health Literature (CINAHL). The included search terms were
selected based on the chosen PICO question. Search terms used in also three searches include
“aprepitant,” “comparison,” “ondansetron OR zofran,” and “PONV.” Additional terms included
in the search strategy for each concept or topic were added to ensure all relevant studies were
identified. The excluded terms were selected based on a large number of irrelevant results
associated with those terms. PUBMED yielded a total of 109 results, EMBASE yielded a total of
76 results, and CINAHL yielded a total of 8 results. Table 1 below contains all detailed
information regarding the conducted search strategy, including exact included search terms,
excluded search terms, applied filters, and the number of results.
Table 1. Database Search Table
Concepts/
Topics

Aprepitant
or Emend

Comparison

Ondansetron or
Zofran

PUBMED aprepitant
OR emend
OR "NK-1
antagonist*"
OR
"Neurokinin

comparison
OR
comparing
OR versus

ondansetron OR
zofran OR
"serotonin 5-HT3
antagonist*" OR
“5-HT3
antagonist*"

Postoperative
Nausea and
Vomiting
"postoperative
nausea and
vomiting" OR
"ponv" OR
"post operative
nausea and

Filters
Applied
125 results
Filter
applied:
publication
date
between
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EMBASE

1 receptor
antagonist*"
OR
"Neurokinin
1
antagonist"
aprepitant
OR emend
OR "NK-1
antagonist*"
OR
"Neurokinin
1 receptor
antagonist*"
OR
"Neurokinin
1
antagonist"
aprepitant
OR emend
OR "NK-1
antagonist*"
OR
"Neurokinin
1 receptor
antagonist*"
OR
"Neurokinin
1
antagonist"

12
vomiting" OR
"nausea and
vomiting"

2007-2020.
Resulted in
109 results
total.

comparison
OR
comparing
OR versus

ondansetron OR
zofran OR
"serotonin 5-HT3
antagonist*" OR
“5-HT3
antagonist*"

"postoperative
nausea and
vomiting" OR
"ponv" OR
"post operative
nausea and
vomiting" OR
"nausea and
vomiting"
NOT
chemotherapy

9 results
Filter
applied:
publication
dates
between
2007-2020.
Resulted in
8 results
total.

comparison
OR
comparing
OR versus

ondansetron OR
zofran OR
"serotonin 5-HT3
antagonist*" OR
“5-HT3
antagonist*"

"postoperative
nausea and
vomiting" OR
"ponv" OR
"post
operative
nausea and
vomiting" OR
"nausea and
vomiting"
NOT
chemotherapy

“Quick
search”
used in all
fields to get
96 results
found
Filters
applied:
Publication
dates
between
2007-2020.
Resulted in
76 total
results.

Study Selection and Screening Method
The program Endnote was utilized for screening, study selection, and organization of
articles. Search results were first imported separately from each database into Endnote. A group
was then created with all 193 articles from the 3 separate databases. Duplicates were then located
using the “Find Duplicates” option in Endnote, which identified a total of 31 duplicate articles.
After the duplicates were removed, a total of 162 articles were left to be screened and assessed for
eligibility in this review. New folders were created for organizational placement during the
screening process with titles “Background,” “Applicable,” and “Not applicable.” During the
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screening process, the investigator reviewed all articles titles and abstracts, and placed each
article in the appropriate folder based on that information. Articles that were clearly unrelated to
the PICO question were placed in the “Not applicable” folder. Articles that were related to the
PICO but needed further review for selection were placed in the “Applicable” folder. Those that
were relevant to the PICO but were not actual studies were placed in the “Background” folder.
The “Not applicable” folder ended up with 111 articles that were excluded in the screening
process, leaving a total of 51 articles for further review.
A full-text screening process was completed by the investigator on all 51 “Applicable”
articles based on strict inclusion and exclusion criteria. A detailed list of the inclusion and
exclusion criteria is displayed in Table 2. Articles that met inclusion criteria included those with a
patient population aged 18 years or older, those that compared a single dose of aprepitant or
aprepitant with ondansetron to ondansetron alone, and those that measured PONV and use of
rescue antiemetics as the outcome. Additional inclusion criteria included publications in the
English language between the dates of 2007 and 2020. Randomized controlled trials (RCTs),
systematic reviews, and meta-analyses were utilized to complete this review. Exclusion criteria
included patients less than 18 years of age, patients receiving chemotherapy, or patients receiving
medications that are known to cause nausea and/or vomiting. Studies that were excluded were
those that involved use of any other antiemetic combination therapy other than ondansetron with
aprepitant for PONV prophylaxis or that studied aprepitant versus ondansetron for use in
prevention of chemotherapy induced nausea and vomiting.
Several studies were excluded because of additional antiemetic agents in conjunction
with aprepitant or ondansetron as the intervention. If any other antiemetic agents were given in
the intervention or comparison, they were excluded to eliminate inaccurate findings, with the
exception of ondansetron with aprepitant as the intervention. A number of studies were also
excluded because chemotherapy or radiation therapy induced nausea and vomiting was studied,
rather than postoperative nausea and vomiting. A total of 193 articles were identified between the
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three databases. After duplicates were removed, 162 articles were screened and assessed for
eligibility. The screening process identified 111 articles for exclusion based on information given
in the article's title and abstract. Another 41 articles were excluded as they did not fit the chosen
PICO question. This left a total of 10 studies relevant to the PICO question to be included in this
review. A PRISMA flow diagram is provided in Figure 1, which displays the full process for
study selection.

Table 2. Inclusion & Exclusion Criteria
Inclusion Criteria
Population
• Age > or = 18 years of age
• Males & Females

Intervention
• Single dose aprepitant for PONV
prophylaxis
• Aprepitant + ondansetron
• General Anesthesia

Comparison
• Ondansetron alone for PONV
prophylaxis
Outcome
• Rates of PONV
• Need for rescue antiemetics
postoperatively
Type of study
• Published between 2007-2020
• Randomized Controlled Trials
• Systematic Reviews
• Meta Analyses
• English language

Exclusion Criteria
Population
• Age < 18 years of age
• Patients receiving chemotherapy
• Patients taking medications that are
known to cause nausea and/or
vomiting
Intervention
• Aprepitant + any other antiemetic
other than ondansetron for PONV
prophylaxis (i.e., Aprepitant +
decadron, Aprepitant + scopolamine)
• Aprepitant vs ondansetron for
chemotherapy induced nausea and
vomiting
• Regional Anesthesia only
Comparison
• Decadron or any other antiemetic
• Total intravenous anesthesia (TIVA)
• No antiemetic
Outcome
• Anything other than PONV or need
for rescue antiemetics
Type of study
• Published before 2007
• Dissertation/theses
• Surveys
• Expert Opinions
• Non-English language
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Identification

Figure 1. PRISMA Flow Diagram

Records identified through
database searching
(n = 193)

Additional records
identified through other
sources
(n = 0)

Included

Eligibility

Screening

Records after duplicates removed
(n = 162)

Records screened
(n = 162)

Full-text articles
assessed for
eligibility
(n = 51)

Studies included in
quantitative
synthesis (metaanalysis)
(n = 10)

Records excluded
(n =111)

Full-text articles
excluded, with reasons
(n = 41)
2 Wrong Comparison
22 Wrong Study
Design
11 Wrong
Interventions
5 Literature Reviews
1 Wrong Language
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Collection, Analysis, & Data Items
The ten identified relevant studies were appraised utilizing John’s Hopkin’s research
evidence appraisal tool.12 This tool helped to rate each study based on its level of evidence and
quality. 12 Evidence level was rated from I to IV, with level I evidence being the highest level of
evidence and level IV being the lowest level of evidence. 12 Level I studies include any
experimental studies, randomized controlled trials (RCTs), systematic reviews of RCTs, or metaanalyses. 12 Level II studies include quasi-experimental studies and systematic reviews of quasiexperimental studies with or without meta-analyses. 12 Level III studies are non-experimental
studies, any systematic reviews including non-experimental studies, or qualitative studies.12 Level
IV studies include expert opinions including opinions of recognized and respected authorities or
organizations.12 This includes expert committees that develop recommendations based on
scientific evidence including clinical practice guidelines and consensus panels. 11
Each study was rated as high quality, good quality, or low quality with major flaws
utilizing John’s Hopkin’s research evidence appraisal tool. 12 A high-quality rating was given to
studies that have an appropriate sample size, proper control, generalizable results, and
recommendations that are consistent with the current literature. 12 Studies were rated as good
quality in the presence of generally consistent results, a reasonable sample size, some control, and
fairly consistent findings and recommendations based on a comprehensive literature review.12
Those considered low quality or with major flaws were those with little evidence or
inconsistencies, those with an inadequate sample size, and those in which conclusions could not
be drawn from the study. 12
The ten studies included in this review included 1 post hoc analysis of two randomized
controlled trials, 5 randomized double blind controlled trials, 2 randomized controlled trials, and
2 systematic review and meta-analyses. All studies included are experimental studies as they
include an intervention, control, randomization, and manipulation of at least 1 variable.12 All
studies were also classified as Level I evidence based on John’s Hopkins research evidence
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appraisal tool.12 Questions that were used to come to this determination for the post hoc analysis
and RCTs included, “Was there manipulation of an independent variable?,” “Was there a control
group?,” “Were study participants randomly assigned to the intervention and control groups?.”12
Each study included in both systematic review and meta-analyses was an RCT, making them both
a Level I evidence study.12 In order to determine the quality of evidence for the RCTs, the
investigator reviewed the article to determine if (1) the problem was clearly identified (2) the
purpose of the study was clearly stated (3) the literature review was current within the last 5 years
(4) the sample size was sufficient (5) the data collection methods were clearly described (6)
reliability and validity were assessed and discussed (7) the results were presented clearly (8) the
limitations were discussed and (9) conclusions were based on the results.12
To determine the quality of evidence for the systematic reviews, the investigator
reviewed the article to determine if (1) the variables of interest were clearly identified (2) the
search was comprehensive and reproducible with mention of multiple search databases, terms,
and inclusion/exclusion criteria (3) there was a flow diagram with a breakdown of the screening
and review process (4) all details included in the studies were presented (5) methods for appraisal
were described (5) conclusions were based on results and (6) limitations were discussed.12 Table 3
below provides a breakdown of the level and quality of evidence for each study included in this
review based on the above mentioned criteria.

Table 3. Study characteristics
Author & Year
Diemunsch P, Apfel
C, Gan TJ, et al.,
2007.

Type of study,
Level and Quality
of Evidence
Post hoc analysis
of pooled data
from two RCTs,
Level I, Good
quality

Participants, Surgical
Procedure, & Setting

Intervention &
Comparison

1599 patients age 18
years or older, ASA IIII, 92% female
population, Mean age=
46, open abdominal
surgery requiring
overnight stay, 82%
were gynecological

Aprepitant 40 mg PO
vs Aprepitant 125 mg
PO vs Ondansetron 4
mg IV
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Diemunsch P, Gan
TG, Philip BK, et al.,
2007.

Randomized
double-blind
controlled trial,
Level I, High
quality

Gan TJ, Apfel CC,
Kovac A, et al., 2007.

Randomized
double-blind
controlled trial,
Level I, High
quality
Randomised
controlled trial,
Level I, High
quality

Ham SY, Shim YH,
Son MJ, et al., 2016

Jeyabalan S, Thampi
SM, Karuppusami R,
Samuel K., 2019.
Lim CS, Ko YH, Park
SI, et al., 2013.

Double blinded,
randomised
controlled trial,
Level I, High
quality
Randomized
controlled trial,
Level I, Good
quality

Liu M, Zhang H, Du
B, et al., 2015.

Systematic
Review and Metaanalysis,
Level I, High
quality

Singh PM, Borle A,
Rewari V, et al., 2016

Systematic
Review and Metaanalysis,
Level I, High
quality
Double-blind
placebo-controlled
trial,

Sinha AC, Singh PM,
Williams NW, et al.,
2014.

surgery, 18% were
non-gynecological
surgery
992 patients age 18
years or older, ASA IIII, open abdominal
surgery, 42 centres
included (8 U.S. sites
and 34 non-U.S. sites
in North America,
South America,
Europe, Australia, and
Asia)
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Aprepitant 40 mg PO
vs Aprepitant 125 mg
PO vs Ondansetron 4
mg IV

805 patients age 18
years or older, ASA IIII, abdominal surgery,
29 centers

Aprepitant 40 mg PO
vs Aprepitant 125 mg
PO vs Ondansetron 4
mg IV

125 female patients age
22-55 years old, ASA 1
& II, gyneacological
laparoscopic surgery,
single-center in Korea
125 female patients
Age 18 -65 years, ASA
I-II, breast and thyroid
surgeries, tertiary care
hospital
90 patients, age 18-65
years old, ASA I-II,
Rhinolaryngological
surgery

Aprepitant 80 mg PO
+ Ondansetron 4 mg
IV vs Ondansetron
4mg IV alone

Sample size varies by
study, age 18 years or
older, ASA I-III,
variety of surgical
procedures, 5
multicenter studies, 9
single-centered studies
Sample size varies by
study, age 18 years or
greater undergoing
elective surgery, single
and multicenter studies
125 morbidly obese
patients, ASA I to III
patients aged 18 years

Aprepitant 40 mg PO
alone vs Ondansetron
8 mg alone
Aprepitant 80 mg +
Ondansetron 4 mg vs
Aprepitant 125 mg +
Ondansetron 4 mg vs
Ondansetron 4 mg
alone
Ondansetron vs
aprepitant alone, &
aprepitant +
ondansetron vs
ondansetron alone
Ondansetron vs
aprepitant alone, &
aprepitant +
ondansetron vs
ondansetron alone
Aprepitant 80 mg +
Ondansetron 4mg vs
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quality

Vallejo MC, Phelps
AL, Ibinson JW, et al.,
2012.

Prospective,
double-blinded,
randomized, twoarm evaluation
study
Level I, Good
quality

or older, patients at
high risk for PONV,
bariatric surgery,
Hospital of the
University of
Pennsylvania in
Philadelphia
150 patients
undergoing outpatient
plastic surgery, males
and females age 18-65
years old
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Placebo +
Ondansetron 4 mg

Aprepitant +
Ondansetron vs
Placebo +
Ondansetron

RESULTS
Study selection
As portrayed in the PRISMA diagram in Figure I, a total of 193 articles were identified
during the initial search process. After the screening process was completed, a total of ten articles
were selected to be included in this review based on strict inclusion criteria. Each of these articles
answers the chosen PICO question: “In patients 18 years or older undergoing general anesthesia,
does the administration of aprepitant, including the combination administration of aprepitant with
ondansetron, compared to ondansetron alone, reduce incidence rates of PONV?” The two
systematic reviews included in this review evaluate both aprepitant with zofran and aprepitant
administration alone with ondansetron alone as the comparison. These articles also include other
combinations of aprepitant that are not included in answering the mentioned PICO question. Four
out of the ten selected articles measure aprepitant alone versus ondansetron alone, and the other
four studies measure combination therapy of ondansetron with aprepitant versus ondansetron
alone. The four studies that measure combination therapy with aprepitant and ondansetron were
also included in this review based on recommendations from the ASA guidelines discussed
earlier that recommend combination therapy for patients at high risk.9 Table 3 above lists each
study selected to be included in this systematic review, along with level of evidence, population,
settings, intervention, and comparison.
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Study characteristics
The eight randomized controlled trials that were included in this review had a total of
4,011 patients who received either aprepitant alone, aprepitant with ondansetron, or ondansetron
alone. Diemunsch et al, Diemunsch et al, and Gan et al contributed the most patients to this
review with 1599, 992, and 805 patients respectively.13,7,9 Patients in the studies conducted by
Diemunsch et al, Diemunsch et al, Gan et al, and Jeyabalan et al received either a dose of
aprepitant alone or a dose of ondansetron alone.13,7,9,14 This included 3,521 total patients. The
remaining 490 patients from RCT studies conducted by Ham et al, Lim et al, Sinha et al, and
Vallejo et al. received either aprepitant in combination with ondansetron or ondansetron
alone.15,16,17,18 All studies were published between 2007 and 2019 in the English language.
Surgical procedures included open abdominal, laparoscopic gynecaeolgical, rhinolaryngeal,
outpatient plastic, breast, thyroid, and bariatric surgeries. One study by Ham et al studied the
efficacy of aprepitant with ondansetron versus ondansetron alone in patients who underwent
laparoscopic gynaecological surgery on a postoperative fentanyl-based patient-controlled
analgesia (PCA) pump with 12 mg of added ondansetron to the PCA solution.15
Patient and hospital demographics. Both male and female patients were included as
part of this review. All studies included both female and male patients with the exception of Ham
et al and Jeyabalan et al, which only included female patients.15,14 Patients ranged from ASA class
I to ASA class III, and all patients were age 18 years or older. One study by Sinha et al studied
morbidly obese patients with a body mass index (BMI) > 40 kg/m3 who were considered at high
risk for PONV.17 The RCTs were conducted across the world including the United States, North
America, South America, Asia, Europe, Australia, and Korea. Most studies were conducted in a
hospital setting with the exception of Vallejo et al that conducted the study in an outpatient plastic
surgery center.18
Methodology. As previously mentioned, patients in all 8 RCTs either studied aprepitant
alone versus ondansetron alone, or aprepitant in combination with ondansetron versus
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ondansetron alone. The dose of aprepitant varied throughout some of the studies. Four RCTs
measured aprepitant versus ondansetron alone, and the other four RCTs measured aprepitant in
combination with ondansetron versus ondansetron alone. Of the RCTs measuring aprepitant
versus ondansetron alone, three studies measured the same doses of aprepitant and ondansetron at
the same time.13,7,9 Diemunsch et al, Diemunsch et al, and Gan et al all randomly assigned patients
via computer randomization to receive preoperative doses of (1) aprepitant 40 mg PO (2)
aprepitant 125 mg PO or (3) ondansetron 4 g IV.13,7,9 In all three of these studies, either aprepitant
or placebo was given 1–3 hours before induction of anesthesia, along with administration of
either intravenous ondansetron or placebo given over 2–5 minutes immediately prior to induction
of anesthesia.13,7,9 The fourth RCT that measured aprepitant versus ondansetron alone was by
Jeyabalan et al, which measured only 1 dose of aprepitant PO.14 Jeyabalan et al randomly
assignment patients to two groups to either receive aprepitant 40 mg PO preoperatively or
placebo, and injection of ondansetron 8mg IV or placebo IV before the end of surgery and again
for two more doses, 8 hours apart.14
The other four RCTs that measured aprepitant as combination therapy with ondansetron
in comparison to ondansetron alone include Ham et al, Lim et al, Sinha et al, and Vallejo et
al.15,16,17,18 All RCTs administered aprepitant 80 mg prior to induction of anesthesia, with the
exception of Vallejo et al that administered 40 mg of aprepitant prior to induction.15,16,17,18 Each of
these RCTs comparing combination therapy of aprepitant and ondansetron versus ondansetron
alone administered one dose of ondansetron at 4 mg, with the exception of Ham et al. 15,16,17,18
Ham et al administered ondansetron 4 mg IV at the end of surgery, and also added 12 mg of
ondansetron the fentanyl based PCA solution that was to be infused in the postoperative period.15
Aprepitant was administered preoperatively in all four RCTs. However, the timing of ondansetron
was different in one of the studies. Lim et al, Ham et al, and Sinha et al all administered
ondansetron just prior to the end of surgery, whereas Vallejo et al administered ondansetron
immediately after induction of anesthesia.15,16,17,18
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All RCTs included in this review assessed nausea scores for 48 hours postoperatively,
except for Sinha et al that assessed nausea scores for 72 hours postoperatively and Jeyabalan et al
that assessed nausea scores for only 24 hours after surgery.7,9,13,14,15,16,17,18 However, nausea scores
were evaluated using different scales, by different methods, and at different time intervals.
Diemunsch et al, Diemunsch et al, Gan et al, and Jeyabalan et al measured nausea scores using
the Verbal Rating Score (VRS), which measures nausea on a scale from ‘0’ to ‘10’ where ‘0’ is
‘no nausea’ and 10 is ‘nausea as bad as it could be.’ 7,9,13,14 Sinha et al and Vallejo et al also used
the VRS scoring system; however, Sinha et al defined a score of ’10’ as ‘worst possible urge to
vomit’ and Vallejo et al defined a score of ‘10’ as ‘worst possible nausea ever.’ 17,18 Diemunsch et
al, Diemunsch et al, and Gan et al assessed patients nausea scores at hours 2, 4, 6, 24 and 48 after
surgery, at any point during the postoperative period that the patient complained of nausea, and
before administration of rescue therapy if needed.7,9,13 Jeyabalan et al assessed patients’ nausea
scores with the VRS scoring system at three different points in the postoperative period: (1) 0-2
hours (2) 2-12 hours and (3) 12-24 hours.14 Sinha et al assessed patients nausea scores 30
minutes, 1 hour, 2 hours, 6 hours, 24 hours, 48 hours, and 72 hours postoperatively.17
Vallejo et al measured nausea scores using the VRS scoring system on admission to
PACU and every hour until the patient was discharged.18 Since the patients used in this study
underwent outpatient surgery, each patient was sent home with a diary to be filled out.18 This
diary required patients to record a nausea score and whether they retched or vomited every four
hours while awake for the first 24 hours, and every 8 hours while awake from 24 to 48 hours
postoperatively.18 Data from these diaries was obtained via a telephone survey from a follow up
with the primary investigator.18 Ham et al utilized the Verbal Numerical Rating Score (VNRS) to
measure the intensity of nausea from ‘0’ to ‘10’ with ‘0’ as ‘no nausea’ and ‘10’ as the ‘worst
nausea imaginable.’15 VNRS scores were assessed during 4 different intervals: (1) 10 minutes
after arrival to the PACU (2) upon PACU discharge to 6 hours postoperatively (3) between 6 to
24 hours postoperatively and (4) between 24 to 48 hours postoperatively.15 These scores were
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record by a nurse blinded to the study.15 Lastly, Lim et al utilized the Rhodes Index of Nausea,
Vomiting, and Retching (RINVR) scoring system to assess patients’ nausea scores
postoperatively. 16 RINVR scores were assessed at 6 hours and 24 hours in the postoperative
period.16 This nausea assessment is based on 8 different questions.16 Based on the response to
each question, a score of 0-4 points is given, with a total possible score of 32.16 A score of 0
signifies no distress or nausea, whereas a score of 32 signifies severe distress or nausea.16
Definitions and Findings of Outcomes
The main variables that were measured throughout the studies were severity of nausea,
retching or vomiting, and use of rescue antiemetics. The severity of nausea was measured using
either the Verbal Rating Score (VRS), the Verbal Numeric Rating Score (VNRS), or the Rhodes
Index of Nausea, Vomiting, and Retching (RINVR) scoring system. 7,9,13,14,15,16,17,18 The RCTs had
similar definitions of nausea, retching, vomiting, and an emetic episode. Gan et al defined an
emetic episode as “one or more continuous episode of vomiting (oral expulsion of stomach
contents) or retching (an attempt to vomit that is not productive of stomach contents); distinct
episodes were those occurring at least 1 min apart.”9 Jeyabalan et al defined an emetic episode as
“a single retch or vomit or any number of continuous vomits or retches.”14 Jeyabalan also defined
retching as “an effort to vomit which is not under voluntary control and that does not cause
expulsion of stomach contents” and vomiting as “an expulsion of stomach contents.”14 Sinha et al
defined retching as “expulsive attempts without any oral content” and vomiting as “as oral
expulsion of gastric contents.”17 Additionally, Sinha et al defined an emetic episode as “any
episode of vomiting or retching.”17
Most studies involved in this review found aprepitant alone to be superior to ondansetron
alone in prevention of postoperative nausea and vomiting. Studies that measured aprepitant as
combination therapy with ondansetron in comparison to ondansetron alone all found combination
therapy with aprepitant to be more efficacious than ondansetron alone.15,16,17,18 Both studies by
Diemunsch et al found aprepitant to be superior to ondansetron in both postoperative nausea and
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vomiting, whereas Gan et al found aprepitant superior only in the prevention of postoperative
vomiting.7,9,13 Diemunsch et al found that administration of aprepitant at doses of 40 mg and 125
mg provided superior protection against nausea, vomiting, and need for rescue antiemetics in
comparison to ondansetron 4 mg IV.13 Overall, patients that were given aprepitant preoperatively
had lower nausea scores than those who received ondansetron alone.13 Diemunsch et al found that
patients who received aprepitant were twice as likely to be protected against vomiting episodes in
comparison to those that only received ondansetron.7 Additionally, time to first vomiting episode
was delayed in those who received aprepitant.7 The dose of aprepitant administered seemed to
have no statistically significant difference in the efficacy of prevention of nausea and vomiting.7
Therefore, it was concluded that a dose of 40 mg of aprepitant is sufficient for PONV
prophylaxis.7 The last RCT that was included in this review that studied ondansetron alone versus
aprepitant alone was Jeyabalan et al, which actually found ondansetron and aprepitant to have the
similar efficaciousness in prevention of PONV.14 There was no significant difference in
prevention of emetic episodes, incidence of nausea, or time to request of rescue antiemetic.14
However, Jeyabalan et al did find that the aprepitant group took longer to develop the first
episode of vomiting and to receive the first dose of rescue antiemetics.14
All four RCTs that measured the combination administration of aprepitant with
ondansetron in comparison to ondansetron alone found that the addition of aprepitant to
ondansetron was superior to that of ondansetron alone in preventing of PONV.15,16,17,18 Ham et al
and Sinha et al both found that the time to first vomiting was prolonged in the patients who
received aprepitant with ondansetron.15,17 According to Sinha et al, nausea scores generally peak
at 4 hours after emergence from anesthesia.17 However, the group that received aprepitant had no
episodes of vomiting during this time period, and up until 6 hours postoperatively, supporting the
hypothesis that aprepitant delays time to first vomiting.17
Recommendations and Limitations
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Limitations existed across the RCTs included in this systematic review that could have
altered nausea scores, vomiting episodes, and use of rescue antiemetics. This could have altered
results and findings from these studies. A few limitations that existed throughout the majority of
the RCTs were that the timing of ondansetron administration and use of rescue antiemetics could
have had a large impact on the severity of nausea, and the subjectiveness of nausea could have
altered results. Jeyabalan et al mentioned that a major limitation to the study was that aprepitant
was administered at a dose of 40 mg, yet previous studies have found that aprepitant is more
efficacious at higher doses of 80 mg and 125 mg.14 Therefore, this could have influenced nausea
scores. The study conducted by Lim et al stated that a limitation to the study was that patients
included in the study did not have a large number of risk factors for PONV, which could have
resulted in patients having low incidences of nausea and vomiting.16 Sinha et al mentioned that
opioid consumption was not compared between the two groups, which could have had an effect
on nausea.17 Vallejo et al mentioned two limitations: (1) patients who required rescue therapy
received standardized treatment based on the institutions protocol for PONV, which may have
affected the patients’ outcomes and (2) ondansetron was administered on induction to ensure that
all patients would receive the medication since the duration of the surgeries varied. Most research
states that ondansetron has improved efficacy just prior to emergence.18
Many of the RCTs discussed recommendations for further studies on aprepitant.
Diemunsch et al and Gan et al both recommended further studies be conducted to determine its
effectiveness in prevention of PONV in other patient populations such as pediatrics.7,9 Diemunsch
et al also recommended further studies on the use of aprepitant in (1) treatment of surgical
patients who already have symptoms of nausea and vomiting (2) combination with a TIVA
approach and (3) combination with other antiemetics as part of a multimodal regimen for PONV
prophylaxis.7 Jeyabalan et al discussed the importance of determining the most optimal dose of
aprepitant in prevention and treatment of postoperative nausea and vomiting.14 Jeyabalan et al
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recommended further studies be conducted to determine aprepitant’s potential interactions with
other antiemetics as well as the cost effectiveness of its use.14
Risk of Bias
Based on the Cochrane Collaboration Risk of Bias tool, there are five sources of bias that
may be evident within a study: selection, performance, detection, attrition, and reporting bias.19
Overall, this systematic review had a low risk for selection bias across the RCTs involved.
Diemunsch et al, Diemunsch et al, Gan et al, and Jeyabalan et al utilized computerized
randomization to select patients for inclusion which eliminated any selection bias.7,9,13,14 Ham et
al and Lim et al did not mention how patients were selected for inclusion.15,16 Sinha et al and
Vallejo et al recruited patients on the day of surgery.17,18 Sinha et al did not specify who recruited
subjects; however, Vallejo et al mentioned that the anesthesiologists involved in care recruited
patients to be subjects in the study.17,18 Therefore, Ham et al, Lim et al, Sinha et al, and Vallejo et
al all had a high risk for selection bias based on the Cochrane Collaboration Risk of Bias
tool.15,16,17,18,19 Allocation of patients was done by computer randomization in all 8 RCTS. Since
allocation was concealed, this avoided selection bias. All RCTs were double-blinded, meaning
that both the investigator and the patient were blinded to the study, except for Lim et al which did
not specify if the investigator knew of the assigned group.7,9,13,14,15,16,17,18 Therefore, this
systematic review has a low risk for performance and detection bias.19
DISCUSSION
Summary of Evidence
Eight RCTs were included in this review, which resulted in a total of 4,011 male and
female patients age 18 years and older. Two systematic reviews that were also included in this
review studied aprepitant with ondansetron as well as other antiemetics such as decadron. All ten
studies included in the review were considered Level I evidence based on John’s Hopkin’s
toolkit.12 The majority of the articles were also considered high quality evidence, with the
exception of 3 articles that were considered good quality.12 Given the limited number of studies
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on aprepitant versus ondansetron, the investigators were unable to maintain a selective patient
population. Therefore, both males and females were included with a variety of different surgical
procedures. Nausea severity, retching, vomiting, and use of rescue antiemetics were used as study
points to measure the antiemetic efficacy of aprepitant in comparison to the most commonly used
antiemetic, ondansetron. These measures were evaluated for 48 hours postoperatively in most of
the studies, except for one study that measured nausea for 24 hours and another that measured
nausea for 72 hours. A summary of the results of this systematic review are stated below:
•

Preoperative administration of aprepitant provides superior protection against nausea,
vomiting, and need for rescue antiemetics in comparison to ondansetron 4 mg IV.13

•

Administration of aprepitant in combination with ondansetron is more effective than
administration of ondansetron alone in prevention of PONV.15,16,17,18

•

Aprepitant is superior to ondansetron in prevention of postoperative vomiting.7,9,13

•

Preoperative administration of aprepitant delays time to first vomiting episode.7,15,16,17

•

Patients who receive aprepitant preoperatively are two times as likely to be protected
against vomiting in comparison to those who receive ondansetron.7

Limitations to this Systematic Review
There are a number of apparent limitations to this systematic review that must be
mentioned. Given the limited number of studies conducted comparing aprepitant to ondansetron,
the investigator was unable to conduct a systematic review with studies that looked at one type of
surgical procedure. Therefore, patients included in the review had variety of different procedures
including open abdominal, laparoscopic gynecaeolgical, rhinolaryngeal, outpatient plastic, breast,
thyroid, and bariatric surgeries. Given the large variety of different procedures, patients included
in the study may have varying degrees of nausea in the postoperative period. Additionally, both
males and females were included in this systematic review. As previously discussed, females
have at least a 20% risk for developing PONV in comparison to males who have no increased risk
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for PONV based on gender.6 Therefore, including both females and males could have affected
nausea scores.
Different doses of aprepitant and ondansetron were administered throughout each of the
studies. Aprepitant was given at doses of 40 mg, 80 mg, and 125 mg based on the study and
ondansetron was given at a dose of 4 mg in most studies, except for 8 mg in one study. All doses
of aprepitant were administered prior to induction of anesthesia; however, ondansetron was given
at different time periods in the perioperative period which could have influenced the severity of
nausea. Lastly, use of rescue antiemetics that were used by patients who had complaints of nausea
in some studies could undoubtedly have influenced nausea scores in the postoperative period.
Recommendations for Future Systematic Reviews
Given the above discussed limitations, future systematic reviews should be conducted
that focus on one specific patient population, preferably the female population given the increased
risk for PONV. One specific procedure or area of surgery, such as laparoscopic gynecological or
abdominal surgery, should be focused on to eliminate the differing effects of the surgical
procedure on severity of nausea experienced postoperatively. Additionally, studies included in
the review should be those with the same dose of aprepitant and ondansetron given at the same
time in the perioperative period. Systematic reviews in the future should also utilize studies that
measured the severity of nausea at the same time postoperatively, with the same scoring system.
Facilitators and Barriers
One facilitator to the use of aprepitant is its ease of administration. Aprepitant is a onetime administration by mouth, that does not require subsequent doses because of its long half-life
of 40 hours.9 The majority of other antiemetics in use require redosing, like the commonly
administered ondansetron. A major barrier to the use of aprepitant is the cost. For example, the
institution involved in the study conducted by Vallejo et al reported a cost of $0.60 for
ondansetron in comparison to $46.60 for aprepitant.18 Therefore, patients must be willing to pay
additional costs to prevent postoperative nausea and vomiting.
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Recommendations for Practice
Based on the findings from this systematic review, it is clear that aprepitant has
demonstrated improved efficacy over ondansetron in prevention of PONV. Aprepitant notably
contributes to delayed time to first vomiting, which may be related to its long half-life. Therefore,
it may be particularly useful in patients whom vomiting in the direct postoperative period may
lead to serious complications. For example, Diemunsch et al suggested that aprepitant may be
especially useful in surgeries requiring postoperative jaw-wiring.7 As previously discussed, use of
antiemetics from different drug classes proves to be more efficacious than that of single agent
antiemetic therapy.8 The ASA recommends use of 1 or 2 interventions for patients at moderate
risk for PONV, and 2 or greater interventions for those at high risk for PONV.9 Therefore, use of
aprepitant in combination with ondansetron may be beneficial in those at risk for PONV, such as
patients of female gender, with a non-smoking history, with a history of PONV, or those with
planned use of postoperative opioids.6 An algorithm for use of aprepitant is displayed in Figure 2.
Conclusion
The aim for this systematic review was to determine if the administration of aprepitant,
including the combination of aprepitant with ondansetron, would be more effective than
ondansetron alone in reducing the incidence rates of PONV in patients 18 years or older
undergoing general anesthesia. Based on the evidence obtained from ten different research
articles, aprepitant administered alone along with aprepitant administered with ondansetron is
more effective than ondansetron alone in reducing PONV rates. While aprepitant may not be cost
efficient in the patient at low risk for PONV, it has the potential to be extremely beneficial in
patients at high risk for PONV. Administration of aprepitant preoperatively was particularly
effective in prevention of postoperative vomiting and time to first vomiting episode.7,9,13,15,16,17
Therefore, aprepitant may also be valuable in cases in which postoperative vomiting could lead to
serious adverse effects, such as the patient requiring postoperative jaw-wiring.7
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It is clear that postoperative nausea and vomiting is an ongoing problem despite a
multitude of improvements in healthcare. PONV rates remain high despite the availability of
multiple antiemetic agents and short-acting anesthetic agents, as well as the development of
minimally invasive surgical techniques.2 Patients have indicated prevention of PONV as being
one of the most concerning effects of receiving general anesthesia and have agreed to pay up to
$100 out of pocket to avoid experiencing nausea or vomiting postoperatively.2 Implementation of
an evidence-based algorithm for administration of aprepitant has the potential to lead to improved
patient outcomes and increased patient satisfaction. An algorithm can help anesthesia providers
identify high risk patients who would benefit from administration of aprepitant. This systematic
review has demonstrated aprepitant’s effectiveness in the prevention of postoperative nausea and
vomiting, and a change to current practice is warranted.
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Figure 2. Aprepitant administration algorithm

Does the patient fall in
2 or more of the
following categories: 1)
Female 2) Non-smoker
3) History of PONV 4)
Planned use of
postoperative opioids

No

Yes

Yes

No

Will postoperative
vomiting result in
severe complications
based on the surgical
procedure?

No

Yes

Is the patient willing to
pay additional costs to
prevent PONV?

No

Is the patient taking any of
the following medications: 1)
pimozide 2) terfenadine 3)
astemizole 4) cisapride or 5)
warfarin

Yes

Adminster
aprepitant

DNP PROJECT ACTION PLAN

Do not administer
aprepitant
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DNP PROJECT ACTION PLAN
Primary Aim
Postoperative nausea and vomiting (PONV) is one most common patient complaints
reported after surgery. 1 In one study, surgical patients rated vomiting as the number 1 most
concerning possible anesthesia outcome. 1 PONV contributes to patient dissatisfaction with
anesthesia, lengthened post-anesthesia recovery unit stays, and increased healthcare costs. 3 It can
cause complications such as pulmonary aspiration, wound dehiscence, esophageal rupture,
pneumothorax, subcutaneous emphysema, and unplanned hospital admission.3 Despite a
multitude of improvements today in healthcare, including the availability of multiple prophylactic
antiemetic agents, the use of minimally invasive surgical techniques, and the availability of shortacting anesthetics, PONV rates still remain high. 2 Incidence rates for inpatient surgeries range
between 30% to 50%, with rates as high as 70% to 80% for patients with multiple risk factors.3 It
is important to stay abreast with the most current evidence-based literature in order to combat the
continued high rates of PONV.
Recent evidence suggests that the NK-1 antagonist, aprepitant, can be remarkably
effective in the prevention of PONV. When aprepitant is administered in combination with
ondansetron, it shows improved effectiveness compared to ondansetron alone. A significant
advantage of aprepitant is its ability to reduce the incidence of postoperative vomiting. Aprepitant
may hold high value in the patient at increased risk for PONV or increased risk for serious
adverse effects in the presence of postoperative vomiting. Recommendations for use of aprepitant
include its use in patients with an Apfel score of 2 or >, or at moderate to high risk for PONV,
and in patients at risk for serious complications related to postoperative vomiting such as those
that require post-operative jaw-wiring. Implementation of an educational module in the form of a
PowerPoint presentation to educate anesthesia providers on aprepitant’s use will be the doctorate
in nursing practice (DNP) action plan and quality improvement (QI) project.
Goals and Outcomes
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The overlying goal for this DNP is to educate anesthesia providers through a PowerPoint
presentation in order for them to make informed decisions and incorporate the use of aprepitant in
their practice. By doing this, the goal is to contribute to decreasing rates of PONV. In order to
evaluate the goals for this DNP project, the SMART model framework was used.20 This
framework is based on the idea that goals should be SMART, which stands for specific,
measurable, achievable, results focused and timely.20 Utilizing this framework ensures that goals
are clearly stated, well-defined, and easily measured. Listed in Figure 3 below are the SMART
goals developed for this DNP project.

Figure 3. SMART Goals
Initial Goal: All anesthesia providers will be educated throught a PowerPoint Presentation on the use of
aprepitant for the prevention of PONV. A pre-test and post-test survey will be distributed electronically
to determine the effectiveness of the educational module. Included in the Powerpoint presentation will
be a background of the problem, evidence-based findings, and recommendations for practice.
•Outcome # 1: By the end of the summer, anethesia providers will be able to discuss the signiciance
of the problem of PONV and ways in which aprepitant can contribute to decreasing rates.
Intermediate Goal: Anesthesia providers will have an increased knowledge base on the NK-1 receptor
antagonist, aprepitant, and be able to state the most appropritate use of aprepitant in the prevention of
PONV.
•Outcome #2: Anesthesia providers will score at least 10 % higher on the post-test survey.
•Outcome #3: Anesthesia providers will be able to state two appropriate uses for aprepitant in the
prevention of PONV such as a patient with an Apfel score of 2 or > or a patient who requires
postoperative jaw wiring.
Long Term Goal: Anethesia providers will state that they recognize the positive impact that aprepitant
could have on decreasing PONV rates.
•Outcome #4: Anesthesia providers will state that they would utilize aprepitant in their practice and
would recommend its use to their collegues.
Ultimate Goal: Adopting apreptiant as part of the hospital's available medications for use and adding a
protocol to the anesthesia group on the use of aprepitant.
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IMPLEMENTATION
Setting and Participants
The quality improvement project was conducted via an online survey that included a
PowerPoint educational module. This was distributed to the members of the Miami Beach
Anesthesiology Associates group at Mount Sinai Medical Center. The participants in the
preliminary study group included anesthesia providers with the title of Certified Registered Nurse
Anesthetist (CRNA) and Anesthesiologist. Participants included in this study were based on an
email list provided by Miami Beach Anesthesiology Associates as part of the anesthesia group
that employs Mount Sinai Medical Center. Participants were asked to complete a pre-survey
questionnaire as well as a post-survey questionnaire to determine the effectiveness of the
educational module in educating anesthesia providers on the use of aprepitant. The anticipated
sample size was between 5-15 participants. After recruitment of subjects was completed, a total
of 7 participants agreed and participated in this study.
Recruitment
The target population for this improvement project were anesthesia providers including
CRNAs and anesthesiologists of whom work in a setting in which care is provided to patients
greater than 18 years of age undergoing general anesthesia. Recruitment of participants was
performed via an online invitation through an email list of anesthesia providers providing direct
anesthesia care services to surgical patients at Mount Sinai Medical Center. Proposed participants
were informed that participation in the study was voluntary and that participants have the right to
withdraw from the study at any time.
Description of Approach and Project Procedures
This project was conducted via email distribution of a virtual educational module through
an online survey software called Qualtrics. The educational module was viewed via a recorded
PowerPoint presentation that was displayed through a YouTube video. This educational module
contained information on the use and effectiveness of the anti-emetic drug, aprepitant, in the
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prevention of PONV in adult patients undergoing general anesthesia. The primary goal for this
intervention was to increases anesthesia providers knowledge of aprepitant to provide anesthesia
providers with the information needed to integrate aprepitant into their practice based on the
evidence obtained from this systematic review. Anesthesia providers existing knowledge on
aprepitant was measured via a pre-survey questionnaire prior to viewing the YouTube video. The
pre-survey questionnaire contained a total of 12 questions on PONV and aprepitant. After the
video was viewed, participants filled out a post-survey questionnaire to determine the
effectiveness of this educational intervention. The post-survey questionnaire was identical to the
pre-survey questionnaire, which included the same 12 questions. The goal with the pre and post
surveys was to test the content of the module to determine if the information contained within it
was effective in the education of anesthesia providers on the antiemetic drug, aprepitant.
The YouTube video was recorded with audio on PowerPoint and uploaded to YouTube to
be viewed by participants. It contained a total of 14 slides including the introduction and
reference slides, and was approximately 7 minutes in length. The video included information
regarding the background on PONV, the importance of addressing PONV, and complications
related to PONV. Additional information included current recommendations for practice on
prevention of PONV and a risk assessment tool that is used to determine patients’ risk for
developing PONV after general anesthesia. Information on the mechanism of action and proper
administration of aprepitant was contained within the video. This included appropriate route and
timing of administration, as well as half-life. This was compared next to the most commonly used
anti-emetic, ondansetron. The educational module included information on the study findings of
aprepitant that were discovered from this systematic review, including aprepitant’s effectiveness
in the prevention of PONV in comparison to ondansetron and in combination with ondansetron.
Recommendations for practice on the use of aprepitant were included and a summary of
information was provided to conclude the content of the video. The educational module offered
anesthesia providers with evidence-based information obtained from multiple different studies as
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mentioned within this systematic review. It allowed anesthesia providers the opportunity to utilize
the information provided to make informed decisions on treatment of patients in the prevention of
PONV.
Protection of Human Subjects
All participants that completed the educational intervention remained anonymous and
data was secured utilizing unique code identifiers. Data collected for this project was protected
with a laptop password and spyware. Only the project team was entitled access to the data
obtained from this project. There were minimal risks associated with this project, as would be
expected with any educational intervention. This could have included mild emotional stress or
mild physical discomfort from sitting on a chair for approximately 20 minutes.
Data Collection and Analysis
The primary instruments used in this study to collect data include the pre-survey
questionnaire and the post- survey questionnaire which were compared to one another to
determine the effectiveness of the educational module on anesthesia providers knowledge of
aprepitant in the prevention of PONV. As previously mentioned, the Qualtrics survey software
program was utilized to distribute and collect data. Unique code identifiers were utilized for
participants that kept participants anonymous to link the pre and post survey questionnaires to the
same participant, in order to more accurately determine the effectiveness of the educational
intervention. The pre-survey questionnaire was intended to determine participants baseline
knowledge of aprepitant, while the post-survey questionnaire was intended to determine the
ability of the educational module to effectively deliver appropriate information on aprepitant. The
data collected in this study remained secured throughout the process, with no participant
identifiers recorded during any part of the study.
Data Management and Measure
The investigator for this project was the DNP student of whom was responsible for
disbursement of surveys to the email list provided by Miami Beach Associates anesthesia group.
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The DNP student was also responsible for collection and measurement of data within the
Qualtrics software system. Each question was measured, and the responses were evaluated to
identify Mount Sinai Medical Center anesthesia providers’ knowledge base on aprepitant. No
personal identifiers were recorded that could be viewed by the investigator. However, a unique
code was utilized to link the same participant to the pre and post survey respectively to accurately
measure responses. The value of this educational module was based upon the results of the pre
and post survey instruments. Through statistical analysis, the results will determine if the
educational module increased anesthesia providers’ knowledge on aprepitant.
IMPLEMENTATION RESULTS
Pre/Post-Test Demographics
The pre-test demographics are as displayed in Table 4., shown below.
Table 4. Pre-Test Participants Demographics
Demographic
Total Participants
Gender
Male
Female
Age
18-29
30-49
40-60
> 60
Ethnicity
White
Asian
Black or African
American
Native Hawaiian or
Pacific Islander
Other
Years of Experience
1 to 2 years
3 to 5 years
6 to 10 years
More than 10 years

n (%)
7 (100%)
3 (43%)
4 (57%)
1 (14%)
6 (86%)
0 (0%)
0 (0%)
5 (72%)
0 (0%)
1 (14%)
0 (0%)
1 (14%)
2 (28.5%)
2 (28.5%)
0 (0%)
3 (43%)
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There were 7 participants in total that participated in this improvement project. Between
the 7 participants, 4 were females (57%) and 3 were males (43%). The majority of participants
were between the ages of 30 and 49 years old (n= 6, 86%). The only other age group that
participated in this study was between 18 and 29 years old (n=1, 14%). The ethnicities
represented within this participant group include white (n=5, 72%), black or African American
(n= 1, 14%), and other (n=1, 14%). The participants were asked the number of years of
experience they have been practicing anesthesia. There was a range in number of years of
experience within the study group including: 1 to 2 years (n= 2, 28.5%), 3 to 5 years (n=2,
28.5%), and more than 10 years (n=3, 43%).
Pre-Test Results on Likelihood to Use and Recommend Aprepitant
The pre-survey questionnaire asked participants their perception on the effectiveness of
aprepitant in PONV prevention, how likely they were to use aprepitant in their practice, and how
likely they were to recommend aprepitant to other anesthesia providers. The goal was to
determine if this educational module would change anesthesia providers’ perceptions of
aprepitant, their willingness to incorporate it into their practice, and their likelihood to
recommend it to other anesthesia providers. Most participants perception of aprepitant in the pretest survey was that aprepitant’s antiemetic effects are effective (n=5, 72%). The last two
participants response to the pre-test survey were that aprepitant’s antiemetic effects are somewhat
effective (n=1, 14%) and most ineffective (n=1, 14%). When asked how likely participants were
to use aprepitant in the prevention of PONV on the pre-test, participants responses were as
follows: most likely (n=1, 14%), somewhat likely (n=5, 72%), and somewhat unlikely (n=1,
14%). Participants were either most likely (n=3, 43%) or somewhat likely (n=4, 57%) to
recommend aprepitant to other anesthesia providers.
Pre-Test and Post-Test Results on Knowledge of PONV and Aprepitant
The survey focuses on determining anesthesia providers current perceptions on PONV,
effectiveness of current practices, and the implications for not addressing the current issue of
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PONV. It also addresses the mechanism of action, pharmacological properties, and effectiveness
of aprepitant in the prevention of PONV. The majority of study participants were not able to
answer correctly to the rates of PONV for inpatient surgeries and to rates of PONV in patients
with multiple risk factors in the pre-test survey. Only 1 participant answered correctly to both of
these questions. All participants answered these questions correctly in the post-test survey. Only 3
out of 7 participants were aware that vomiting has been reported as one of the most concerning
possible anesthesia outcomes in the pre-test survey, and all participants answered correctly in the
post-test survey. In the pre-test survey, 57% (n=4) answered correctly to aprepitant’s mechanism
of action, whereas in the post-test survey all respondents answered correctly. The majority of
participants did not understand the pharmacological properties of aprepitant in the pre-test survey
with only 2 (29%) participants answering correctly. All respondents answered the question on the
pharmacological properties of aprepitant correctly on the post-test survey. Complications of
PONV and consequences of failing to address PONV as a problem was well understood by all
participants in the pre-test survey. The differences between Pre- and Post-test responses are
displayed in Table 5.
Table 5. Differences in Pre- and Post-Test Knowledge
Questions

Pretest
14%

Posttest
100%

Difference
86%

Patients with multiple risk factors experience postoperative
nausea and vomiting (PONV) at rates as high as:

14%

100%

86%

Complications of PONV include:

100%

100%

0%

Patients have reported that _________ is one of the most
concerning possible anesthesia outcomes.

43%

100%

57%

Failure to address PONV as a problem will result in:

100%

100%

0%

All of the following are independent risk factors for PONV
according to the Apfel scoring system, EXCEPT:

86%

100%

14%

Postoperative nausea and vomiting (PONV) rates for inpatient
surgeries range between:

APREPITANT VERSUS ONDANSETRON FOR PONV

40

Patients given antiemetics such as the commonly used 5-HT3
antagonist, ondansetron, still experience PONV ______of the
time.

0%

14%

14%

Aprepitant exerts its antiemetic effects via:

57%

100%

43%

All of the following are true of aprepitant EXCEPT:

29%

100%

71%

Post-Test Results on Likelihood to Use and Recommend Aprepitant
In the post-test questionnaire, 6 participants (86%) responded that aprepitant’s antiemetic
effects are effective, and 1 participant (14%) responded that aprepitant’s antiemetic effects are
somewhat effective. Overall, respondents reported that they were more likely to use aprepitant in
the prevention of PONV after viewing the YouTube video. In the pre-test survey 1 participant
responded they were most likely to use it, 5 participants responded they were somewhat likely to
use it, and 1 participant responded they were somewhat unlikely to use it. However, in the posttest survey, 4 participants responded that they were most likely to use aprepitant in the prevention
of PONV and 3 responded that they were somewhat likely to use it. Lastly, in the pre-test survey
3 participants reported that they were most likely to recommend the use of aprepitant to other
anesthesia providers and 4 participants reported they were somewhat likely to recommend its use.
In the post-test survey, more participants (n= 5, 71%) were most likely to recommended
aprepitant to other anesthesia providers in comparison to the pre-test survey (n=3, 43%). The rest
of the participants (n=2, 29%) in the post-test survey reported they were somewhat likely to
recommended aprepitant to other anesthesia providers.
Summary
Overall, the results from the pre and posttest surveys reflected an improvement in
participant knowledge on PONV and the antiemetic drug, aprepitant. In the pre-test survey, the
mean score was 49%, whereas in the post-test survey the mean score was 90%. This showed an
increase of 41% on anesthesia provider knowledge. Additionally, more participants reported that
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they were most likely to use aprepitant in the prevention of PONV and recommend aprepitant to
other anesthesia providers in comparison to the pre-test responses.
IMPLEMENTATION DISCUSSION
Limitations
Limitations to this study include the small sample size of only 7 participants. The email
list provided by Miami Beach Anesthesiology Associates anesthesia group contained 31 people.
However, only 7 responded and agreed to participate in this study. A larger sample size would
have been preferred to obtain the most accurate results that would more appropriately reflect
Mount Sinai Medical Center’s anesthesia providers. Another limitation is that the survey link was
sent out and only available for approximately 1 month. A longer time frame could have results in
a larger sample size, and a more representative sample population. Lastly, the project was
conducted exclusively online, which prevented it from being dispersed by other means that may
have yielded a larger sample size as well.
Future Implications for Anesthesia Practice
The practice of anesthesia requires providers, including CRNAs and anesthesiologists, to
stay abreast regarding the most current evidence for treatment of patients in the perioperative
period. This includes remaining up to date on newer pharmacological therapies such as aprepitant
in the prevention of PONV. Educational modules, such as the one utilized in this study, can be
helpful and effective in educating anesthesia providers on such updates within anesthesia. Short
and concise presentations such as the 7-minute recorded PowerPoint presentation on PONV and
aprepitant can add value to the anesthesia practice and allow providers to make more informed
decisions on use of new therapies.
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Appendix

Identification

Appendix A: PRISMA Flow Diagram

Records identified through
database searching
(n = 193)

Additional records
identified through other
sources
(n = 0)

Included

Eligibility

Screening

Records after duplicates removed
(n = 162)

Records screened
(n = 162)

Full-text articles
assessed for
eligibility
(n = 51)

Studies included in
quantitative
synthesis (metaanalysis)
(n = 10)

Records excluded
(n =111)

Full-text articles
excluded, with reasons
(n = 41)
2 Wrong Comparison
22 Wrong Study
Design
11 Wrong
Interventions
5 Literature Reviews
1 Wrong Language
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Appendix D: QI Consent

CONSENT TO PARTICIPATE IN A QUALITY IMPROVEMENT PROJECT
“An Education Intervention on the Use of Aprepitant versus Ondansetron in the Prevention of
Postoperative Nausea and Vomiting (PONV) in Adult Patients Undergoing General Anesthesia.”
PURPOSE OF THE PROJECT
You are being asked to be in a quality improvement project. The goal of this project is to increase
anesthesia providers’ knowledge on the use and effectiveness of the anti-emetic drug, aprepitant.
Through an educational intervention, anesthesia providers will be given the necessary information
on how and when utilization of aprepitant can be beneficial in the prevention of postoperative
nausea and vomiting in adult patients undergoing general anesthesia.
DURATION OF THE PROJECT
Your participation will require about 20 minutes of your time.
PROCEDURES
If you agree to be in the project, we will ask you to do the following things:
RISKS AND/OR DISCOMFORTS
There are no foreseeable risks with you for participating in this project.
BENEFITS
The following benefits may be associated with your participation in this project: An increase in
cholesterol management knowledge, which will help you to better assess medication adherence
and guidelines implementations to reduce the risk of cardiovascular events. The overall objective
of the program is to increase the quality of healthcare delivery, improving the health indicator of
our patients, and increase patient engagement.
ALTERNATIVES
There are no known alternatives available to you other than not taking part in this project.
However, if you like to receive the educational material given to the participants in this project, it
will be provided to you at no cost.
CONFIDENTIALITY
The records of this project will be kept private and will be protected to the fullest extent provided
by law. If, in any sort of report, we might publish, we will not include any information that will
make it possible to identify you as a participant. Records will be stored securely, and only the
project team will have access to the records.
COMPENSATION & COSTS
There is no cost or payment to you for receiving the health education and/or participating in this
project.
RIGHT TO DECLINE OR WITHDRAW
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Your participation in this project is voluntary. You are free to participate in the project or
withdraw your consent at any time during the project. Your withdrawal or lack of participation
will not affect any benefits to which you are otherwise entitled. The investigator reserves the
right to remove you without your consent at such time that they feel it is in the best interest.
RESEARCHER CONTACT INFORMATION
If you have any questions about the purpose, procedures, or any other issues relating to this
research project, you may contact Alyssa Staubitz at 516-241-0306, astau008@fiu.edu or Dr.
Fernando Alfonso at 305-348-3510, falfonso@fiu.edu
IRB CONTACT INFORMATION
If you would like to talk with someone about your rights of being a subject in this project or about
ethical issues with this project, you may contact the FIU Office of Research Integrity by phone at
305-348-2494 or by email at ori@fiu.edu
PARTICIPANT AGREEMENT
I consent by participating in the survey. I have read the information in this consent form and
agree to participate in this project.
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Appendix E: QI Project Survey

Pretest and Posttest Questionnaire:
Prevention of Postoperative Nausea and Vomiting (PONV)
INTRODUCTION
The primary aim of this QI project is to improve anesthesia providers’ knowledge on the use
and effectiveness of the anti-emetic drug, aprepitant, in order to decrease rates of postoperative
nausea and vomiting and improve patient outcomes.
Please answer the question below to the best of your ability. The questions are either in
multiple choice or true/false format. These questions are meant to measure knowledge and
perceptions on management of postoperative nausea and vomiting, including the use and
effectiveness of the neurokinin-1 antagonist, aprepitant.
PERSONAL INFORMATION
1. Gender: Male

Female

Other

Caucasian

African American

2. Age: ______
3. Ethnicity:
Hispanic

Asian Other

4. Position/Title: _________________________________
5. Level of Education: Associates

Bachelors

Masters

Other

___________
6. Years of experience: Less than 1 year

1 to 5

6 to 10

more than 10 years
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QUESTIONNAIRE
1. Postoperative nausea and vomiting (PONV) rates for inpatient surgeries range
between:
a. 5 - 10 %
b. 15 – 30 %
c. 30 – 50 %
d. 70 – 80%
CORRECT ANSWER: C
2. Patients with multiple risk factors experience postoperative nausea and vomiting
(PONV) at rates as high as:
a. 20 - 30 %
b. 30 – 40 %
c. 50 – 60 %
d. 70 – 80%
CORRECT ANSWER: D
3. Complications of PONV include:
a. Pulmonary aspiration
b. Wound dehiscence
c. Pneumothorax
d. Unplanned hospital admission
e. All of the above
CORRECT ANSWER: E
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4. Patients have reported that _________ is one of the most concerning possible
anesthesia outcomes.
a. Pain
b. Vomiting
c. Nausea
d. Death
CORRECT ANSWER: B
5. Failure to address PONV as a problem will result in:
a. Continued patient dissatisfaction with anesthesia
b. Lengthened post-anesthesia recovery unit (PACU) stays
c. Increased healthcare costs
d. All of the above
CORRECT ANSWER: D
6. All of the following are independent risk factors for PONV according to the Apfel
scoring system, EXCEPT:
a. Female gender
b. Current smoker
c. History of PONV and/or motion sickness
d. Use of postoperative opioids.
CORRECT ANSWER: B
7. Patients given antiemetics such as the commonly used 5-HT3 antagonist,
ondansetron, still experience PONV ______ of the time.
a. 5 - 10 %
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b. 10 - 20 %
c. 30 – 40 %
d. 40 – 50%
CORRECT ANSWER: C
8. Aprepitant exerts its antiemetic effects via:
a. Neurokinin-1 receptor antagonism
b. Serotonin-5-HT3 receptor antagonism
c. Dopamine-2 receptor antagonism
d. Histamine-1 receptor antagonism
CORRECT ANSWER: A
9. All of the following are true of aprepitant EXCEPT:
a. It has a long half-life of 40 hours.
b. It is administered orally.
c. It must be re-dosed every 6 hours.
d. It is superior to ondansetron in prevention of postoperative vomiting.
CORRECT ANSWER: C
10. Aprepitant’s antiemetic effects are
a. Effective
b. Somewhat effective
c. Somewhat ineffective
d. Most ineffective
11. How likely are you to use aprepitant in the prevention of PONV?
a. Most likely
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b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
12. How likely are you to recommend aprepitant to other anesthesia providers?
a. Most likely
b. Somewhat likely
c. Somewhat unlikely
d. Most unlikely
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Appendix F: Educational Module
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Appendix G: Project Poster
The Use of Aprepitant Versus Ondansetron in the Prevention of Postoperative Nausea and
Vomiting (PONV) in Adult Patients Undergoing General Anesthesia
Alyssa Staubitz, MSN, RN; Fernando Alfonso, DNP, CRNA; Andrew Gonzalez, DNP, CRNA
Florida International University Nicole Wertheim College of Nursing and Health Sciences

BACKGROUND

RESULTS

PONV, along with pain, is one of two of the most common
patient complaints reported after surgery and is the
leading cause of unplanned inpatient admissions.1 In one
study of surgical patients, patients rated vomiting as the
number one most concerning possible anesthesia
outcome.1 Despite the increasing number of advances in
healthcare, PONV rates remain high.2 Aprepitant has
demonstrated promising effectiveness in the prevention of
PONV and can add value to current healthcare practices.

• Preoperative administration of aprepitant provides
superior protection against nausea, vomiting, and
need for rescue antiemetics in comparison to
ondansetron 4 mg IV.8
• Administration of aprepitant in combination with
ondansetron is more effective than administration of
ondansetron alone in prevention of PONV.7,9,10,,11
• Aprepitant is superior to ondansetron in prevention
of postoperative vomiting.4,5,8
• Preoperative administration of aprepitant delays
time to first vomiting episode.4,7,9,10
• Patients who receive aprepitant preoperatively are
two times as likely to be protected against vomiting
in comparison to those who receive ondansetron.4

PICO

PURPOSE
This systematic review aims to evaluate the current
literature on aprepitant regarding its effectiveness in the
prevention of PONV. The goal is to determine its
effectiveness in comparison to the most commonly used
antiemetic, ondansetron.

(P) In patients 18 years or older undergoing general anesthesia, (I) does the administration
of aprepitant, including the combination of aprepitant with ondansetron, (C) compared to
ondansetron alone (O) reduce incidence rates of PONV?

CLINICAL SIGNIFICANCE
Incidence rates for inpatient surgeries range between 30%
to 50%, with rates as high as 70% to 80% for patients with
multiple risk factors.3 Patients given antiemetics such as
the commonly used 5-HT3 antagonist, ondansetron, still
experience PONV 30% to 40% of the time.4 Aprepitant has
been approved and shown to be effective for the treatment
of chemotherapy-induced nausea and vomiting.4 Recently,
more studies have been conducted regarding its
effectiveness in the treatment and prevention of PONV.

METHODOLOGY
• Research articles were obtained by searching the
following databases: PUBMED, CINAHL, & EMBASE.
• Keywords: aprepitant, NK-1 antagonist, emend,
ondansetron, serotonin 5-HT3 antagonist, and PONV
• Inclusion criteria: RCTs, systematic reviews and meta
analyses published between 2007-2020, studies
measuring aprepitant alone and aprepitant +
ondansetron

Literature Review
Author & Year

Design Sample

Major Findings

Diemunsch P, Gan TG,
Philip BK, et al., 2007.

RCT

Patients taking aprepitant were two times as likely to be protected against
vomiting in comparison to those taking ondansetron.4 Aprepitant delayed time
to first vomiting in comparison to ondansetron.4

Gan TJ, Apfel CC, Kovac
A, et al., 2007.

RCT

Aprepitant at doses of 40 mg PO and 125 mg PO demonstrated delayed time
to first vomiting in comparison to ondansetron alone.5

Singh PM, Borle A,
Rewari V, et al., 2016.

Systematic Review
and Meta-analysis

Aprepitant showed improved efficacy in prevention against vomiting on postop days 1 and 2 in comparison to ondansetron.6

Sinha AC, Singh PM,
Williams NW, et al.,
2014.

RCT

Aprepitant administered with ondansetron showed improved efficacy in
prevention of vomiting and time to first vomiting episode in comparison to
ondansetron alone.7

RECOMMENDATIONS
FOR PRACTICE
• Administer aprepitant in patients at moderate to
high risk for PONV, or in patients with 2 or more
risk factors on the Apfel scoring system.
• Administer aprepitant in patients at risk for serious
complications related to postoperative vomiting.
• Administer aprepitant as combination therapy with
ondansetron for more effective PONV prophylaxis.
• Administer aprepitant no greater than 3 hours prior
to induction of anesthesia at a dose of 40 mg PO.
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